Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of LDE225 dosing schedules in adult acute leukemia
NL-OMON40210Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2013
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sonidegib in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Novartis. Primary endpoint: Complete remission rate. Started Aug 2013; status: active, not recruiting.
02
Drugs
sonidegib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON40210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40210.